Beximco Pharma Ltd

SWOT ANALYSIS 

Strength:

Diversification
The strength of Beximco Pharmaceuticals Ltd. lies in its diversified products and dosage forms.BPL has been producing solid products like tablets and capsules and liquid products like syrup, suspension and solution, as well as semisolid products like cream and ointment. It is the pioneer company to manufacture and market nasal sprays, inhalation aerosols and suppositories in Bangladesh. In 2001, Beximco Pharmaceuticals Ltd. stepped into a new path--bringing SmallVolume Parenteral(SVP) or injectable dosage form. Arixon is it's first small volume injectable product It is a preparation of Ceftriaxone, which is considered as a breakthrough antibiotic in the history of medicine, . In 2002, Arixon is predicted to be one of our leading brands interms of sales revenue. The company has lot of diversified products like, Napa: Neoceptin R: Neofloxin: Tycil : Aristovit M etc.

Achivement of National Export Trophy
 First export market operation with finished pharmaceutical products1994-95 : Achievement of National Export Trophy (Gold) as the first pharmaceutical company of the country.

R & D
B P L is a company that is continuously searching for the next treatment advancements. BPL's portfolio features a range of high-quality, effective products. This product portfolio, combined with the steady stream of promising new products in development, is one of the many reasons BPL is among the nation's leading pharmaceutical companies.We have introduced 26 new products in 2001. Around 70 new products are in our development pipeline. They will obviously enrich our portfolio toeloypment of the employees so that they can cope with the rapidly changing business
environment. Innovation is a major priority that we want to promote. Accordingly, training programs are regularly undertaken for the staff to seek opportunities for skills
improvement.

Weakness:

Opportunities:

BPL always tried to add new products of different therapeutic classes in its portfolio and these products are highly appreciated by the health professionals. Most important of them are Triocim, Arixon, Prosan, Recox, Atova etc.Introduction of these new products enriched it's product portfolio and is contributing to enhance it's sales.Apart from all these, we have intensifiedand consolidated our marketing efforts inother overseas markets, like Myanmar,Kenya,Yemen and Vietnam. To capitalizeimmense opportunities in these overseasmarkets, we are bringing in more new andexciting brands in these markets. Last year,BPLdonated one 'Medical InformationK i o s k ' to the Myanmar MedicalAssociation ofMandalay which gainedenormous attention and acceptance in theminds of the medical community ofM y a n m a r. In Kenya, number of salespeople has been increased to best exploititshuge market potentials. All these effortsare already bringing in desired results.Entering into new horizons andestablishing new overseas markets willremain our top most priority in 2002 also.Russia, Ukraine, Sri Lanka, Cambodia,Nepal will be on the list. We are confidentthat ourprocess of globalization willcontinue with a more and moreaccelerated speed in the coming days.

Technology
Keeping pace with the advanced world
Technology carries the promise of tomorrow. The benefits of technology belong to all of usbenefits that create new opportunities and open doors toa better life. For example, the new inhaler plant of BPL has been designedin a way to ensure highest-possible quality at every stage of manufacturingand quality control. World-class facilities are being employed in each and every step including mixing, filling, testing, labelling, batch printing andother procedures to ensure manufacturing of world class products.

Threats:

BPL has a commitment to the society to supply world class Active Pharmaceutical Ingredients (APIs). Therefore, BPL is not only engaged in formulations but also in fine chemicals business with a view to supplying cost effective quality materials to other local companies as well as for captive consumption.

Beximco Pharmaceuticals Ltd. has been preparing itself for the post-WTO open market competition. It has all the courage to compete with world leaders in pharmaceuticals business when the tariff and non-tariff barriers will be withdrawn The new USFDA standard plant is planned to be operational in early 2003. Once completed, this will be one of the finest facilities to be available anywhere in the globe.